Clinical Focus ›› 2025, Vol. 40 ›› Issue (12): 1142-1146.doi: 10.3969/j.issn.1004-583X.2025.12.016
Previous Articles Next Articles
-
Received:2025-09-23Online:2025-12-20Published:2025-12-30
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.12.016
| [1] |
Huang P, Zhang J. Global leukemia burden and trends: A comprehensive analysis of temporal and spatial variations from 1990-2021 using GBD (Global Burden of Disease) data[J]. BMC Public Health, 2025, 25(1): 262. doi: 10.1186/s12889-025-21428-w.
pmid: 39838416 |
| [2] | Sun J, Zhang YC, Wei J, et al. Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: A nationwide representative multicenter study[J]. Bone Marrow Transplant, 2025, 60(3): 319-325. doi: 10.1038/s41409-024-02485-y. |
| [3] | Guo X, Luo W, Wu L, et al. Natural products from herbal medicine self-assemble into advanced bioactive materials[J]. Adv Sci (Weinh), 2024, 11(35): e2403388. doi: 10.1002/advs.202403388. |
| [4] | Elbadawi M, Boulos JC, Dawood M, et al. The novel artemisinin dimer isoniazide ELI-XXIII-98-2 induces c-MYC inhibition, DNA damage, and autophagy in leukemia cells[J]. Pharmaceutics, 2023, 15(4):1107. doi: 10.3390/pharmaceutics15041107. |
| [5] |
Chen S, Gan S, Han L, et al. Retraction to artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia[J]. Ann Transl Med, 2022, 10(19): 1079. doi: 10.21037/atm-2022-29.
pmid: 36330398 |
| [6] |
Shang X, Dai L, Cao X, et al. Natural products in antiparasitic drug discovery: Advances, opportunities and challenges[J]. Nat Prod Rep, 2025, 42(9): 1419-1458. doi: 10.1039/d5np00007f.
pmid: 40501439 |
| [7] | Brown GD. The biosynthesis of artemisinin (Qinghaosu) and the phytochemistry of Artemisia annua L.(Qinghao)[J]. Molecules, 2010, 15(11): 7603-7698. doi: 10.3390/molecules15117603. |
| [8] | Wen L, Chan BC, Qiu MH, et al. Artemisinin and its derivatives as potential anticancer agents[J]. Molecules, 2024, 29(16):3886. doi: 10.3390/molecules29163886. |
| [9] | Cheong DHJ, Tan DWS, Wong FWS, et al. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases[J]. Pharmacol Res, 2020, 158:104901. doi: 10.1016/j.phrs.2020.104901. |
| [10] |
Herrmann L, Yaremenko IA, Çapcı A, et al. Synthesis and in vitro study of artemisinin/synthetic peroxide-based hybrid compounds against SARS-CoV-2 and cancer[J]. ChemMedChem, 2022, 17(9): e202200005. doi: 10.1002/cmdc.202200005.
pmid: 35187791 |
| [11] |
Huang Y, Yang Y, Liu G, et al. New clinical application prospects of artemisinin and its derivatives: A scoping review[J]. Infect Dis Poverty, 2023, 12(1): 115. doi: 10.1186/s40249-023-01152-6.
pmid: 38072951 |
| [12] | Agrawal PK, Agrawal C, Blunden G. Artemisia rxtracts and artemisinin-based antimalarials for COVID-19 management: Could these beeffective antivirals for COVID-19 treatment?[J]. Molecules, 2022, 27:3828.doi: 10.3390/molecules28217337. |
| [13] |
Lu X, Efferth T. Repurposing of artemisinin-type drugs for the treatment of acute leukemia[J]. Semin Cancer Biol, 2021, 68:291-312. doi: 10.1016/j.semcancer.2020.05.016.
pmid: 32485311 |
| [14] | Mancuso RI, Foglio MA, Olalla Saad ST. Artemisinin-type drugs for the treatment of hematological malignancies[J]. Cancer Chemother Pharmacol, 2021, 87(1): 1-22. doi: 10.1007/s00280-020-04170-5. |
| [15] | Ma Z, Woon CY, Liu CG, et al. Repurposing artemisinin and its derivatives as anticancer drugs: A chance or challenge?[J]. Front Pharmacol, 2021, 12:828856. doi: 10.3389/fphar.2021.828856. |
| [16] | Bhowmick S, Lee YJ. ER stress induced by artemisinin and its derivatives determines the susceptibility to their synergistic apoptotic killing with TRAIL[J]. Cancer Med, 2025, 14(12): e71001. doi: 10.1002/cam4.71001. |
| [17] | Xu Q, Deng H, Huang X, et al. Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties[J]. Eur J Med Chem, 2025, 281:117018. doi: 10.1016/j.ejmech.2024.117018. |
| [18] | Tan M, Rong Y, Su Q, et al. Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells[J]. Leuk Res, 2017, 62:98-103. doi: 10.1016/j.leukres.2017.09.022. |
| [19] | Witalisz-Siepracka A, Denk CM, Zdársky B, et al. STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance[J]. Front Immunol, 2024, 15:1374068. doi: 10.3389/fimmu.2024.1374068. |
| [20] |
Pirali M, Taheri M, Zarei S, et al. Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells[J]. Int J Biol Macromol, 2020, 164:3369-3375. doi: 10.1016/j.ijbiomac.2020.08.198.
pmid: 32861782 |
| [21] | Liu Y, Li H, Luo Z, et al. Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe(2+) pathways[J]. Br J Pharmacol, 2023, 180(6): 701-720. doi: 10.1111/bph.15986. |
| [22] | Posadino AM, Giordo R, Pintus G, et al. Medicinal and mechanistic overview of artemisinin in the treatment of human diseases[J]. Biomed Pharmacother, 2023, 163:114866. doi: 10.1016/j.biopha.2023.114866. |
| [23] |
Yang X, Zheng Y, Liu L, et al. Progress on the study of the anticancer effects of artesunate[J]. Oncol Lett, 2021, 22 (5): 750. doi: 10.3892/ol.2021.13011.
pmid: 34539854 |
| [24] |
Tang N, Liu X, Liu Y, et al. Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4-CHOP signaling pathway[J]. Oncol Lett, 2024, 28 (1): 337. doi: 10.3892/ol.2024.14470.
pmid: 38846431 |
| [25] | Ishikawa C, Senba M, Mori N. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma[J]. Eur J Pharmacol, 2020, 872: 172953. doi: 10.1016/j.ejphar.2020.172953. |
| [26] |
Yu Y, Yan Y, Niu F, et al. Ferroptosis: A cell death connecting oxidative stress, inflammation and cardiovascular diseases[J]. Cell Death Discov, 2021, 7(1): 193. doi: 10.1038/s41420-021-00579-w.
pmid: 34312370 |
| [27] | Chen YS, Chuang WC, Kung HN, et al. Pan-caspase inhibitor zVAD induces necroptotic and autophagic cell death in TLR3/4-stimulated macrophages[J]. Mol Cells, 2022, 45 (4): 257-272. doi: 10.14348/molcells.2021.0193. |
| [28] | 陈璨, 黄永芬, 苗雨青. 老年急性髓样白血病的治疗进展[J]. 临床荟萃, 2023, 38 (10): 954-960. doi: 10.3969/j.issn.1004-583X.2023.10.018. |
| [29] |
Grignano E, Cantero-Aguilar L, Tuerdi Z, et al. Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: Links to iron metabolism and metallothionein[J]. Cell Death Discov, 2023, 9 (1): 97. doi: 10.1038/s41420-023-01371-8.
pmid: 36928207 |
| [30] | Pan W, Shen Y, Luo B, et al. Dihydroartemisinin induces autophagic cell death in acute myeloid leukemia cells through oxidative stress[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2022, 30 (4): 1011-1017. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.006. |
| [31] |
Kudo Y, Hirota K, Tsuzuki H, et al. Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells[J]. J Biochem, 2025, 178 (1): 11-24. doi: 10.1093/jb/mvaf022.
pmid: 40329484 |
| [32] | Zhang X, Ai Z, Zhang Z, et al. Dihydroartemisinin triggers ferroptosis in multidrug-resistant leukemia cells[J]. DNA Cell Biol, 2022, 41 (8): 705-715. doi: 10.1089/dna.2021.1145. |
| [33] | Zhou X, Suo F, Haslinger K, et al. Artemisinin-type drugs in tumor cell death: Mechanisms, combination treatment with biologics and nanoparticle delivery[J]. Pharmaceutics, 2022, 14 (2):395. doi: 10.3390/pharmaceutics14020395. |
| [34] | Xu C, Zhang H, Mu L, et al. Artemisinins as anticancer drugs:novel therapeutic approaches, molecular mechanisms, andclinical trials[J]. Front Pharmacol, 2020, 11: 529881. doi: 10.3389/fphar.2020.529881. |
| [35] |
Jhade SK, Kalidoss K, Pathak PK, et al. Artemisinin's molecular symphony: Illuminating pathways for cancer therapy[J]. Mol Biol Rep, 2024, 52 (1): 95. doi: 10.1007/s11033-024-10202-7.
pmid: 39739138 |
| [36] |
Huang X, Yan H, Xu Z, et al. The inducible role of autophagy in cell death: Emerging evidence and future perspectives[J]. Cell Commun Signal, 2025, 23 (1): 151. doi: 10.1186/s12964-025-02135-w.
pmid: 40140912 |
| [37] | Lin L, Tang Z, Shi Z, et al. New insights into artesunate as a pleiotropic regulator of innate and adaptive immune cells[J]. J Immunol Res, 2022, 2022: 9591544. doi: 10.1155/2022/9591544. |
| [38] | Gao P, Shen S, Li X, et al. Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis[J]. Drug Des Devel Ther, 2020, 14: 2091-2100. doi: 10.2147/dddt.S248872. |
| [39] |
Hu W, Chen SS, Zhang JL, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation[J]. Cancer Lett, 2014, 343 (2): 239-248. doi: 10.1016/j.canlet.2013.09.035.
pmid: 24099910 |
| [40] | Zhou Z, Lei J, Fang J, et al. Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases[J]. Int Immunopharmacol, 2024, 139: 112637. doi: 10.1016/j.intimp.2024.112637. |
| [41] | Liu J, Han X, Zhang T, et al. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: From mechanism to therapy[J]. J Hematol Oncol, 2023, 16 (1): 116. doi: 10.1186/s13045-023-01512-7. |
| [42] | Marchesi E, Perrone D, Navacchia ML. Molecular hybridization as a strategy for developing artemisinin-derived anticancer candidates[J]. Pharmaceutics, 2023, 15 (9):2185. doi: 10.3390/pharmaceutics15092185. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||